Erasca Inc
Research Erasca Inc (ERAS) on Bullrun: market cap USD 4.99B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerERAS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.99B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 44.08M
- Free cash flow-USD 27.28M
Valuation Snapshot
latest market cap is USD 4.99B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 124.55M | -USD 95.58M | n/a | -0.44 | USD 73.81M | USD 47.14M | USD 325.17M |
| FY2024 | USD 0 | -USD 161.65M | -USD 109.48M | n/a | -0.69 | USD 67.74M | USD 51.89M | USD 423.50M |
| FY2023 | USD 0 | -USD 125.04M | -USD 102.99M | n/a | -0.83 | USD 93.08M | USD 55.86M | USD 316.69M |
| FY2022 | USD 0 | -USD 242.81M | -USD 117.82M | n/a | -1.99 | USD 284.22M | USD 55.10M | USD 411.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 4.99B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.06B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 710.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 321.82M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 646.73M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.86B | n/a | n/a | n/a |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Erasca Inc's market cap?
Erasca Inc's market capitalization is USD 4.99B.
What does Erasca Inc do?
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.